Creative Medical Technology Holdings Expands Collaboration with Greenstone Biosciences to Accelerate iPSCelz Pipeline Development
MWN-AI** Summary
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology firm focusing on regenerative medicine, has announced an expanded partnership with Greenstone Biosciences to enhance its human induced pluripotent stem cell (iPSC) platforms, particularly targeting diabetes treatment. This collaboration will leverage Artificial Intelligence (AI) to further develop Creative Medical's proprietary hypoimmune iPSC technology, specifically in producing iPSC-derived pancreatic islet cells. These cell lines, derived from Good Manufacturing Practice (GMP) grade human perinatal cells, are currently undergoing clinical trials aimed at addressing critical medical needs.
The integration of AI-driven methodologies is expected to optimize the identification of small molecules that boost insulin secretion, thereby increasing the therapeutic effectiveness of these hypoimmunogenic pancreatic islet cells. Additionally, the partnership plans to explore multi-gene editing techniques to enhance the stealth capability, survival, and differentiation potential of future hypoimmune iPSC lines. This is vital as the typical requirement for immunosuppression in stem cell therapies can lead to severe side effects. By focusing on the refinement of hypoimmune iPSC lines, Creative Medical is working towards creating safer, more effective cell-based therapies for diabetes and potentially other chronic conditions.
Timothy Warbington, President and CEO of Creative Medical, expressed optimism about the collaboration, highlighting its anticipated efficiency in reducing research and development time by about 50% and generating significant cost savings. This innovative approach positions Creative Medical as a key player in personalized medicine, leveraging AI and genetic engineering to tackle some of today’s most pressing healthcare challenges.
MWN-AI** Analysis
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is gaining traction as it expands its collaboration with Greenstone Biosciences to implement AI in enhancing its induced pluripotent stem cell (iPSC) technology for diabetes therapy. As a clinical-stage biotechnology firm, Creative Medical stands to benefit significantly from this partnership, which aims to streamline the development of its hypoimmune iPSC-derived pancreatic islet cells.
Investors should pay close attention to the implications of AI integration in R&D processes. CEO Timothy Warbington remarks that this collaboration could shorten research timelines by 50% and yield substantial cost savings. Such advancements may position Creative Medical favorably against competitors in the rapidly evolving field of regenerative medicine.
The focus on multi-gene editing to create hypoimmune iPSCs that can evade immune detection is particularly noteworthy. The potential to eliminate the need for immunosuppressive therapies could profoundly enhance patient outcomes and drive demand for Creative Medical’s offerings. Success in this area could not only validate its proprietary technologies but also lead to expansion beyond diabetes into other serious medical conditions, creating a broader market impact.
However, investors should also remember the inherent risks associated with clinical-stage biotechnology firms. The market is highly volatile and driven by clinical trial results, regulatory approvals, and broader economic conditions. As Creative Medical advances its research, stay vigilant about trial outcomes and any regulatory hurdles that may arise.
In summary, Creative Medical Technology offers promising investment potential due to its innovative approach, strategic collaborations, and the significant unmet medical needs it aims to address. Investors may consider monitoring its progress closely, balancing excitement for its advancements with awareness of the risks that come with biotech investment.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PHOENIX, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical”) , a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced an expanded agreement with Greenstone Biosciences Inc. (“Greenstone”) to leverage Artificial Intelligence (AI) in further developing its human induced pluripotent stem cell (iPSC) platform for diabetes treatment.
This strategic collaboration extends the progress made on Creative Medical’s proprietary hypoimmune iPSC technology, including its iPSC-derived pancreatic islet cells. These innovative cell lines, developed from Good Manufacturing Practice (GMP) grade human perinatal cells, are currently being used in clinical trials. By integrating AI-driven drug discovery, the partnership aims to identify small molecules that enhance insulin secretion, further refining the therapeutic potential of Creative Medical’s hypoimmunogenic iPSC-derived pancreatic islet cells. Additionally, the program will implement multi-gene editing to develop next generation hypoimmune iPSC lines with enhanced stealth, survival, and differentiation capabilities. These advancements will not only optimize pancreatic islet cell function but also expand the platform’s applications to other regenerative therapies, addressing critical unmet medical needs.
Addressing a Major Clinical Challenge
One of the most pressing challenges in stem cell-based therapies is the requirement for immunosuppression, which can lead to severe side effects, including mortality. By refining hypoimmune iPSC lines through AI-guided development, Creative Medical is actively working to overcome these barriers, paving the way for safer and more effective cell-based treatments for diabetes and other chronic conditions.
Leadership Perspective
“Creative Medical is at the forefront of regenerative medicine, and our extended partnership with Greenstone Biosciences marks a significant milestone in our mission to develop transformative therapies,” said Timothy Warbington, President and CEO of Creative Medical.
“Dr. Wu and his team at Greenstone have been instrumental in validating and advancing our proprietary iPSC platform. By incorporating AI-driven methodologies, we estimate that this program will reduce R&D time by approximately 50% compared to other methods and produce millions of dollars in cost savings. We are poised to accelerate innovation, enhance therapeutic efficacy, and position ourselves as a leader in the evolving landscape of personalized medicine.”
Advancing Multi-Gene Edited Hypoimmune iPSCs
The next phase of development focuses on multi-gene edited hypoimmune iPSCs—cells engineered with precise modifications to evade immune detection, improve survival, and optimize therapeutic potential. These cutting-edge advancements offer the potential to eliminate the need for immunosuppression, significantly improving patient outcomes in cell-based regenerative therapies.
As Creative Medical continues to push the boundaries of regenerative medicine, this collaboration reinforces its commitment to leveraging AI and genetic engineering to address some of the most pressing challenges in modern healthcare.
About Creative Medical Technology Holdings, Inc.
Creative Medical Technology Holdings, Inc. is a clinical-stage biotechnology company dedicated to developing groundbreaking regenerative therapies using stem cell and immune modulation technologies. The company’s pipeline targets a range of conditions, with a focus on diabetes, autoimmune disorders, orthopedic and neurological diseases. For more information, visit www.creativemedicaltechnology.com .
Forward-Looking Statements
This press release contains forward-looking statements under the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements reflect the Company’s current views but are not guarantees of future results.
Contact:
Creative Medical Technology Holdings, Inc.
IR@CreativeMedicalTechnology.com
Investor Relations:
Devin Sullivan, Managing Director
The Equity Group Inc.
dsullivan@equityny.com
FAQ**
How does Creative Medical Technology Holdings Inc. CELZ plan to integrate AI-driven methodologies into the development of its hypoimmune iPSC platform for diabetes treatment, and what specific advancements are anticipated from this collaboration with Greenstone Biosciences?
Could you elaborate on how the multi-gene editing of hypoimmune iPSCs by Creative Medical Technology Holdings Inc. CELZ may impact the need for immunosuppression in cell-based therapies, potentially enhancing patient outcomes in diabetes treatment?
What specific cost savings and time reductions in R&D does Creative Medical Technology Holdings Inc. CELZ estimate will result from incorporating AI in its research, and how does this position the company in the competitive landscape of regenerative medicine?
Could you detail the range of conditions beyond diabetes that Creative Medical Technology Holdings Inc. CELZ aims to address with its innovative regenerative therapies, and how the collaboration with Greenstone Biosciences supports this broader mission?
**MWN-AI FAQ is based on asking OpenAI questions about Creative Medical Technology Holdings Inc. (NASDAQ: CELZ).
NASDAQ: CELZ
CELZ Trading
3.38% G/L:
$1.99 Last:
5,542 Volume:
$1.945 Open:
